Background: We have reported promising outcomes using a staged approach, in which bortezomib/thalidomide/ dexamethasone was used only in 14 patients with suboptimal response to VAD (vincristine/adriamycin/ dexamethasone) before autologous stem cell transplantation (ASCT). Here we compared the outcomes of the staged approach with frontline PAD (bortezomib/doxorubicin/dexamethasone) or VTD (bortezomib/thalidomide/ dexamethasone) induction, and analysed prognostic factors for outcome.
Background
Bortezomib, a proteasome inhibitor, is an active agent for the treatment of myeloma. Its efficacy was initially demonstrated in the salvage treatment of refractory myeloma patients, with a complete response (CR) rate of 9% [1, 2] . Subsequently, a high CR rate has also been shown with the use of bortezomib-based regimens as induction therapy for newly diagnosed myeloma patients [3] . A post-induction CR rate of 43% and 30% was observed when bortezomib-based induction regimens were used in both transplant-eligible and transplantineligible myeloma patients [4, 5] .
In Hong Kong, we have adopted a staged approach, in which newly diagnosed, transplant-eligible myeloma patients are risk-stratified according to their initial chemosensitivity. Patients who respond to vincristine, adriamycin and dexamethasone (VAD) undergo autologous stem cell transplantation (ASCT). Patients who do not respond optimally to VAD receive salvage therapy with bortezomib/thalidomide/dexamethasone (VTD) before ASCT. This staged approach aims at employing early bortezomib-based therapy in patients who do not achieve a rapid cytoreduction after VAD, thereby restricting the use of the expensive bortezomib to patients with suboptimal response to conventional treatment while ensuring "early" bortezomib-based induction therapy. With this strategy, a CR rate of 48% (by an intention-to-treat analysis), and a 3-year overall survival of 75%, has been achieved [6] . Based on this approach, we showed that only 56% myeloma patients required salvage therapy with VTD. During the same study period, two other bortezomib-containing regimens VTD and PAD (bortezomib, doxorubicin, dexamethasone) were also used as first-line treatment of myeloma patients.
In this report, we examined the hypothesis that myeloma patients treated by the staged approach, in which early bortezomib-based induction is used in selected patients, might achieve similar outcomes as compared with patients receiving receiving frontline bortezomibbased regimens.
Patients and methods

Patients
Ninety-one newly diagnosed, symptomatic, transplanteligible myeloma patients with measurable disease were studied. Patients who were financially competent received frontline therapy with bortezomib-containing regimens. Other patients received a staged approach, and were treated with bortezomib supported by philanthropy only when the initial response was suboptimal.
Regimens
Staged approach
Twenty-five patients received initial cytoreduction with three cycles of VAD (vincristine, adriamycin and dexamethasone). (Figure 1 ) Those achieving ≥ 75% reduction in paraprotein proceeded to ASCT (N = 11; 44%). Patients with < 75% reduction in paraprotein received salvage therapy with four cycles of VTD (bortezomib: 1.3 mg/m 2 /day intravenously on days 1, 4, 8 and 11; thalidomide: 200 mg/day; dexamethasone: 40 mg/d orally from days 1-4 and days [8] [9] [10] [11] , and then ASCT (N = 14; 56%). All patients received thalidomide (50-100 mg/day) as maintenance therapy post-ASCT. 
Bortezomib-containing regimens
Stem cell mobilization and conditioning
Stem cells were mobilized with cyclophosphamide (3 g/m 2 intravenously) and granulocyte-colony stimulating factor (300 microgram/day subcutaneously until leucocyte recovery). At least 4 x 10 6 CD34+ cells/Kg recipient body weight were collected. ASCT conditioning regimen comprised intravenous melphalan 200 mg/m 2 .
Staging and laboratory investigations
Myeloma work-up included bone marrow examination, skeletal survey, serum β 2 -microglobulin (β 2 M) level, serum protein electrophoresis (SPE), urine protein electrophoresis (UPE), serum or urine immunofixation, paraprotein level assay and serum free light chain (FLC) assay (Freelite, The Binding Site, Birmingham, UK) [7] .
Fluorescence in-situ hybridization (FISH)
Detection of cytogenetic aberrations was performed on myeloma cells in the bone marrow sample by FISH. Enrichment for myeloma cells was achieved by sorting with CD138 immunomagnetic beads (MiniMACS, Miltenyi Biotec, Auburn, CA) if the percentage of myeloma cells were below 50% of all nucleated cells after haematopathology review. The FISH probes (Abbott Molecular, Abbott Park, IL) comprised the IGH/FGFR3 dual colour dual fusion translocation probe for detection of t(4;14) (p16;q32), the IGH/MAF dual colour dual fusion translocation probe for detection of t(14;16)(q32;q23) and TP53/CEP17 dual colour probe for the detection of p53 deletion, in accordance with the International Myeloma Workshop Consensus recommendation. At least 200 nuclei were analyzed and scored independently by two persons. The cutoff for positivity was above 5% or at least 10 positive nuclei based on test validation data. Highrisk (HR) karyotypes include t(4;14), t(14;16) or del(17p).
Response criteria
All patients were analyzed on an intention-to-treat basis. Bone marrow plasmacytosis and paraprotein levels were assessed prior to treatment, after VAD, after VTD, and 3 and 6 months after ASCT. Responses were defined according to standard criteria [8] . Complete remission (CR) was defined as complete resolution of disease with absent paraprotein, as evidenced by a negative SPE and immunofixation, and <5% plasma cells in the bone marrow. Near-complete remission (nCR) was defined as a negative SPE but positive immunofixation. Partial response (PR) was subclassified into very good partial remission (VGPR, paraprotein reduction >90%), and PR (paraprotein >50% reduction). Minor response (MR) was defined as paraprotein reduction of >25% but <50%. No response (NR) was defined as paraprotein reduction of <25%. Progression was defined as >25% paraprotein increase in two consecutive tests four weeks apart. Relapse was defined as reappearance of the paraprotein on immunofixation in CR patients, positive SPE in the nCR patients, and/or appearance of new bone lesions. For patients with light chain myeloma, CR was defined as normalization of the level and ratio of serum FLC, and negative serum and urine immunofixation.
Statistical analysis
OS was defined as time from commencement of induction therapy to death or last follow-up. Event-free survival (EFS) was defined as time from commencement of induction therapy to the date of progression, relapse or death. Patients were clinically staged according to the international staging system (ISS) [9] . Survival curves were plotted by Kaplan-Meier method and compared by the log-rank test. 
Treatment results
The post-induction CR/nCR rate were 24%, 41.9% and 42.9% in patients receiving the staged approach, PAD and VTD respectively (p = 0.268). Post-induction ≥ VGPR rates were 56%, 74.2 % and 63.3% in patients receiving the staged approach, PAD and VTD respectively (p = 0.064). While there was a trend of lower ≥ VGPR rate in patients receiving the staged approach compared with frontline PAD or VTD, the difference disappeared after ASCT (post-ASCT ≥ VGPR rate in staged approach, PAD and VTD were 79.2%, 93.5% and 90%; p = 0.242). Of the whole group of 91 patients, the overall CR/nCR rate and ≥ VGPR rates were 37.4% and 72.5% after induction therapy, and 62.6% and 82.4% after ASCT.
Prognostic indicators
To identify potential risk factors impacting the achievement of CR/nCR or ≥ VGPR either post-induction or post-ASCT, parameters including regimen, isotype, ISS gender or presence of high-risk karyotype were correlated with the achievement of CR/nCR and ≥ VGPR post-induction and post-ASCT ( 
Survivals
In this combined cohort, the 5-year OS and event-free (EFS) survivals were 66% and 45.1% (median EFS: 48 months) ( induction ( Figure 5B ) and failure of CR post-ASCT predicted inferior EFS. In multivariate analysis, advanced ISS and failure of post-ASCT CR/nCR predicted an inferior OS, whereas advanced ISS and failure of CR/nCR post-induction predicted a inferior EFS (Table 4) .
Discussion
There are several observations from the study. Firstly, despite this being a retrospective study, we showed that there was no difference in EFS or OS in patients receiving the staged approach and those receiving frontline PAD or VTD, suggesting that the staged approach yielded comparable survivals as patients receiving frontline bortezomib. This is encouraging because only half [14 (56%)] of the patients receiving the staged approach required salvage VTD, and hence the staged approach could be used as a cost-effective but effective regimen in less affluent countries, where frontline bortezomib might not be affordable for the majority of the population. However, while not reaching statistical significance due to the small number of patients, it is notable that the CR/nCR rate of patients receiving frontline bortezomibbased induction was much higher than that of those induced with the staged approach (42.9% versus 24%). Moreover, the 5-year EFS of patients receiving frontline bortezomib-based induction was almost double that of those induced with the staged approach (69.8% versus 36.3%). Similarly, the 5-year OS of patients receiving frontline bortezomib-based induction was much higher than that of those induced with the staged approach (73.8% versus 59.8%). Therefore, whether significant survival difference may emerge between the staged approach and PAD/VTD after prolonged follow-up remains to be seen. Interestingly, while there was a trend of lower ≥ VGPR rate compared to patients receiving PAD or VTD, the difference was abolished after ASCT. Secondly, a high post-induction CR/nCR (PAD: 41.9%; VTD: 42.9%) and ≥ VGPR rates (PAD: 74.3%; VTD: 83.9%) were observed in patients receiving frontline PAD or VTD induction. These post-induction CR/nCR rates were comparable to other phase II studies, which also reported a high post-induction CR/nCR rate after PAD (29%) or CyBorD (46%) [4, 10] .
Thirdly, we attempted to analyse prognostic factors impacting outcome in this combined cohort of myeloma patients receiving either frontline (PAD/VTD induction) or early bortezomib-based induction (in the staged approach). We showed that ISS III remained an important adverse risk factor predicting both inferior OS and EFS, despite patients receiving early or frontline bortezomibbased induction regimens followed by ASCT. However, there was no association between ISS III and presentation parameters including age, gender, isotype or even high-risk karyotypes. Moreover, ISS III did not result in an inferior CR/nCR or ≥ VGPR rate either postinduction or post-ASCT. Therefore, ISS III is a factor that predicted residual chemo-refractory disease, thereby leading to subsequent fatal relapse or disease progression. Indeed, the adverse prognostic impact of advanced ISS stage for progression-free survival has also been demonstrated in phase III studies [11, 12] . Importantly, ways to improve the survivals of ISS III myeloma patients are urgently needed. In this connection, new targeted agents or next generation immunomodulatory agents are urgently required [13] . This is particularly important in this era of targeted therapy when the adverse prognostic impact of high-risk karyotypes were shown to be at least partially, if not totally, overcome by the use of bortezomib-based induction regimens. [14] The persistence of the unfavorable prognostic impact of advanced ISS despite bortezomib-based induction poses an important therapeutic challenge.
In addition, we showed that post-induction CR/nCR predicted a superior EFS, and CR/nCR post-ASCT a superior OS. This is consistent with recent studies that 
